Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$19.86 - $26.93 $116,677 - $158,213
5,875 Added 5.86%
106,160 $2.68 Million
Q2 2023

Aug 14, 2023

BUY
$16.44 - $21.1 $1.65 Million - $2.12 Million
100,285 New
100,285 $2.12 Million
Q2 2022

Aug 11, 2022

SELL
$17.07 - $25.71 $2.09 Million - $3.14 Million
-122,204 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$20.42 - $28.13 $302,011 - $416,042
-14,790 Reduced 10.8%
122,204 $2.87 Million
Q4 2021

Feb 09, 2022

BUY
$25.89 - $33.45 $3.55 Million - $4.58 Million
136,994 New
136,994 $3.73 Million
Q2 2021

Aug 11, 2021

SELL
$24.17 - $36.01 $4.51 Million - $6.71 Million
-186,428 Closed
0 $0
Q1 2021

May 07, 2021

BUY
$32.28 - $44.3 $96,840 - $132,900
3,000 Added 1.64%
186,428 $6.35 Million
Q4 2020

Feb 03, 2021

BUY
$31.45 - $40.54 $5.77 Million - $7.44 Million
183,428 New
183,428 $6.11 Million
Q2 2019

Aug 07, 2019

SELL
$23.0 - $32.19 $4.31 Million - $6.03 Million
-187,286 Closed
0 $0
Q1 2019

May 01, 2019

BUY
$13.91 - $31.15 $126,928 - $284,243
9,125 Added 5.12%
187,286 $5.44 Million
Q4 2018

Feb 04, 2019

BUY
$11.6 - $18.7 $485,204 - $782,183
41,828 Added 30.68%
178,161 $2.34 Million
Q3 2018

Oct 25, 2018

BUY
$18.95 - $28.08 $491,392 - $728,142
25,931 Added 23.49%
136,333 $2.76 Million
Q2 2018

Aug 02, 2018

BUY
$20.0 - $29.72 $510,620 - $758,781
25,531 Added 30.08%
110,402 $2.61 Million
Q2 2018

Jul 25, 2018

SELL
$20.0 - $29.72 $357,620 - $531,423
-17,881 Reduced 17.4%
84,871 $2.65 Million
Q1 2018

May 01, 2018

BUY
$21.69 - $32.99 $387,838 - $589,894
17,881 Added 21.07%
102,752 $2.31 Million
Q4 2017

Feb 05, 2018

BUY
$26.43 - $31.78 $2.24 Million - $2.7 Million
84,871
84,871 $2.65 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $10B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.